Edwards Lifesciences (NYSE: EW) reported Q1 EPS of $0.60, $0.03 better than the analyst estimate of $0.57. Revenue for the quarter came in at $1.34 billion versus the consensus estimate of $1.31 billion.

GUIDANCE:

Edwards Lifesciences sees Q2 2022 EPS of $0.61-$0.69, versus the consensus of $0.65. Edwards Lifesciences sees Q2 2022 revenue of $1.36-1.44 billion, versus the consensus of $1.46 billion.

Edwards Lifesciences sees FY2022 EPS of $2.50-$2.65, versus the consensus of $2.55. Edwards Lifesciences sees FY2022 revenue of $5.5-6 billion, versus the consensus of $5.76 billion.

For earnings history and earnings-related data on Edwards Lifesciences (EW) click here.